<DOC>
	<DOCNO>NCT00177255</DOCNO>
	<brief_summary>This phase II study investigate weekly dose docetaxel combination capecitabine advance gastric gastro-esophageal adenocarcinoma .</brief_summary>
	<brief_title>A Study Docetaxel Combination With Capecitabine Stomach Esophagus Cancers</brief_title>
	<detailed_description>This phase II study investigate weekly dose docetaxel combination capecitabine advance gastric gastro-esophageal adenocarcinoma . Docetaxel 30mg/m2 administer day 1 8 cycle capecitabine 825mg/m2 bid ( total daily dose 1650mg/m2 ) administer orally 14 day ( day 1-14 ) cycle . Each cycle 21 day . Subjects receive unlimited cycle docetaxel capecitabine evidence disease progression unacceptable side effect .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Have histologically cytologically confirm locally advanced ( unresectable ) metastatic adenocarcinoma gastric , gastroesophageal , esophageal origin . 2 . Must measurable evaluable disease . 3 . Received adjuvant therapy eligible adjuvant therapy give â‰¥ 6 month prior diagnosis metastatic disease . 4 . Life expectancy great 12 week . 5 . ECOG performance status &lt; 2 . 6 . Adequate organ marrow function . 7 . Preexisting peripheral neuropathy present must grade 0 1 . 8 . Women men childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , least 3 month thereafter . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential 1 . No chemotherapy radiotherapy within 4 week 2 . Not receive investigational agent participate investigational drug study within 4 week precede start study treatment . 3 . Patients know brain metastasis shall exclude clinical trial 4 . Patients evidence history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precludes informed consent interferes compliance oral drug intake also exclude . 5 . History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 . 6 . History allergic reaction attribute compound similar chemical biologic composition docetaxel , capecitabine 5FU . 7 . Uncontrolled intercurrent illness 8 . Pregnant breast feed woman exclude study 9 . Inability swallow tablet malabsorptive symptom exclude . 10 . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction docetaxel capecitabine . 11 . Prior use docetaxel capecitabine allow ( Prior 5FU therapy allow ) . 12 . Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer . 13 . Major surgery ( i.e laparotomy , line placement consider major surgery ) within 4 week start study treatment , without complete recovery . 14 . Known , exist uncontrolled coagulopathy . 15 . Patients anticonvulsant metabolize via P450 3A4 pathway .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>gastric</keyword>
	<keyword>stomach</keyword>
	<keyword>esophagus</keyword>
	<keyword>esophageal</keyword>
</DOC>